시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 비교리스트
세계의 Drug Discovery 분야 생성형 인공지능(AI) 시장 보고서(2024년)
Generative Artificial Intelligence (AI) In Drug Discovery Global Market Report 2024
상품코드 : 1526969
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 5,000 ￦ 7,234,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 7,500 ￦ 10,851,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 10,000 ￦ 14,469,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

Drug Discovery 분야 생성형 인공지능 시장 규모는 향후 몇 년 동안 연평균 30.7%의 CAGR로 2028년까지 5억 7,000만 달러 규모로 성장할 것으로 예상됩니다. 예측 기간 동안의 성장은 비용 효율적인 Drug Discovery에 대한 수요, 시장 기업 간의 협력 확대, 컴퓨팅 성능 향상, 생성형 AI와 다른 신흥 기술과의 통합, 신속한 의약품 개발 등 여러 요인에 기인하는 것으로 보입니다. 예측 기간 동안 주요 동향으로는 기술 발전, 생성형 AI와 실험생물학과의 통합, 신약 파이프라인 가속화를 위한 고처리량 스크리닝, 약물 재사용을 위한 AI 기반 플랫폼 개발, 협업 신약개발을 위한 클라우드 기반 AI 솔루션 채택 증가 등이 있습니다.

임상시험의 증가는 신약 개발 시장에서 생성형 AI의 확장을 촉진할 것으로 예상됩니다. 임상시험은 인간 자원 봉사자가 참여하여 새로운 치료법이나 시술의 안전성과 효능을 평가하는 것을 목표로 하며, 인간이 사용할 수 있는 귀중한 과학적 데이터를 제공합니다. 의학 연구 발전, 질병 부담 증가, 규제 변화, 임상 연구의 세계화, 환자 옹호, 업계 경쟁, 기술 발전, 자금 가용성 등 여러 가지 요인이 임상시험의 증가에 기여하고 있습니다. 임상시험 데이터는 상호작용을 예측하고 화합물 설계를 통해 Drug Discovery를 가속화하는 생성형 AI 모델의 입력으로 작용합니다. 이러한 협력은 개인화된 의료를 가능하게 하고, 치료 효과를 높이고, 환자 결과를 개선하며, 의약품의 상황을 변화시킬 수 있습니다. 예를 들어, ClinicalTrials.gov는 2022년 437,512건에서 2023년 말까지 477,234건의 전 세계 임상시험 등록을 보고하고 있으며, 이는 임상시험이 신약개발에서 생성적 AI 채택을 촉진하는 데 있어 임상시험이 매우 중요한 역할을 하고 있음을 강조하고 있습니다.

생성형 AI Drug Discovery 시장의 주요 업체들은 신약개발 프로세스를 가속화하기 위해 AI 기반 첨단 툴을 개발하고 있습니다. 이러한 도구는 AI와 머신러닝을 활용하여 예측 분석을 통해 신약 개발, 설계 및 임상시험을 간소화합니다. 이러한 도구는 표적 식별, 화합물 스크리닝, 전임상 개발, 규제 준수 및 제조의 효율성을 높입니다. 예를 들어, 2023년 5월 구글 클라우드는 두 가지 획기적인 AI 기반 솔루션인 Target and Lead Identification Suite와 Multiomics Suite를 발표했습니다. 이러한 솔루션은 신약 개발 및 정밀 의료를 개선하여 생명공학, 제약 및 공공 부문 조직을 지원합니다. Target and Lead Identification Suite는 연구자들이 아미노산 기능을 이해하고 단백질 구조를 예측하는 데 도움을 주며, Multiomics Suite는 유전체 데이터 분석을 가속화하여 맞춤형 치료법 개발을 촉진합니다.

목차

제1장 주요 요약

제2장 시장의 특징

제3장 시장 동향과 전략

제4장 거시경제 시나리오

제5장 세계의 시장 규모와 성장

제6장 시장 세분화

제7장 지역별·국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 상황과 기업 개요

제31장 기타 주요 기업과 혁신적 기업

제32장 경쟁 벤치마킹

제33장 경쟁 대시보드

제34장 주요 인수합병

제35장 향후 전망과 잠재적 분석

제36장 부록

ksm
영문 목차

영문목차

Generative AI in drug discovery utilizes advanced machine learning techniques, particularly generative models, to create and identify new pharmaceutical compounds. These AI systems analyze vast datasets encompassing chemical properties, biological activity, and existing drug information to predict and generate novel molecules with potential therapeutic benefits. The primary goal is to expedite the discovery of novel pharmaceutical compounds with therapeutic potential, streamlining the drug development process by leveraging extensive data to efficiently predict and generate new molecules.

The main types of generative artificial intelligence (AI) in drug discovery are small molecule and large molecule. Small molecules are chemically synthesized drugs with typically low molecular weights. Various technologies including deep learning, machine learning, reinforcement learning, molecular docking, and quantum computing are employed by a range of end-users, including pharmaceutical and biotechnology companies, academic and research institutions, contract research organizations (CROs), and others.

The generative artificial intelligence (AI) in drug discovery market research report is one of a series of new reports from The Business Research Company that provides generative artificial intelligence (AI) in drug discovery market statistics, including generative artificial intelligence (AI) in drug discovery industry global market size, regional shares, competitors with a generative artificial intelligence (AI) in drug discovery market share, detailed generative artificial intelligence (AI) in drug discovery market segments, market trends and opportunities, and any further data you may need to thrive in the generative artificial intelligence (AI) in drug discovery industry. This generative artificial intelligence (AI) in drug discovery market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The generative AI in drug discovery market size has grown exponentially in recent years. It will grow from $0.15 billion in 2023 to $0.19 billion in 2024 at a compound annual growth rate (CAGR) of 30.6%. The growth in the historic period can be attributed to several factors, including the rising prevalence of chronic diseases, the development of new drug discoveries and clinical trials, the support for AI integration into healthcare and drug development, the growth of biotech industries, and increasing governmental support.

The generative AI in drug discovery market size is expected to see exponential growth in the next few years. It will grow to $0.57 billion in 2028 at a compound annual growth rate (CAGR) of 30.7%. The growth in the forecast period can be attributed to several factors, including the demand for cost-effective drug discovery, which drives the adoption of generative AI, growing collaborations among market players, increasing computational power, integration of generative AI with other emerging technologies, and rapid drug development. Major trends in the forecast period include advancements in technologies, the integration of generative AI with experimental biology, high-throughput screening for accelerated drug discovery pipelines, the development of AI-driven platforms for drug repurposing, and the rising adoption of cloud-based AI solutions for collaborative drug discovery efforts.

The increasing number of clinical trials is anticipated to drive the expansion of generative AI in the drug discovery market. Clinical trials, involving human volunteers, aim to evaluate the safety and efficacy of new medical treatments or procedures, providing valuable scientific data for human use. Several factors contribute to the rise in clinical trials, including advancements in medical research, heightened disease burden, regulatory shifts, globalization of clinical research, patient advocacy, industry competition, technological progress, and funding availability. Clinical trial data serves as input for generative AI models, which accelerate drug discovery by predicting interactions and designing compounds. This collaboration enables personalized medicine, enhances treatment effectiveness, improves patient outcomes, and transforms the pharmaceutical landscape. For example, ClinicalTrials.gov reported a global registration of 477,234 clinical trials by the end of 2023, up from 437,512 trials in 2022, underscoring the pivotal role of clinical trials in driving generative AI adoption in drug discovery.

Key players in the generative AI drug discovery market are developing sophisticated AI-powered tools to expedite drug development processes. These tools leverage AI and machine learning to streamline drug discovery, design, and clinical trials through predictive analytics. They enhance efficiency in target identification, compound screening, preclinical development, regulatory compliance, and manufacturing. For instance, in May 2023, Google Cloud introduced two groundbreaking AI-driven solutions, the Target and Lead Identification Suite and the Multiomics Suite. These solutions empower biotech, pharmaceutical, and public sector organizations by improving drug discovery and precision medicine. The Target and Lead Identification Suite aids researchers in understanding amino acid functions and predicting protein structures, while the Multiomics Suite accelerates genomic data analysis, facilitating the development of personalized treatments.

In May 2023, Recursion Pharmaceuticals acquired Cyclica and Valence for $40 million and $47.5 million, respectively, bolstering its drug discovery capabilities through advanced technologies. These acquisitions position Recursion as a prominent hub for top-tier professionals in machine learning and AI, poised to innovate and shape the future of drug discovery. Cyclica Inc., based in Canada, specializes in data-driven drug discovery and artificial intelligence. Valence Labs, also based in Canada, focuses on advancing AI in drug discovery.

Major companies operating in the generative artificial intelligence (AI) in drug discovery market are Bayer AG, NVIDIA Corporation, Merck KGaA, IBM Research, Schrodinger Inc., Valo Health, BenevolentAI, XtalPi Inc., Insilico Medicine Inc., Recursion Pharmaceuticals Inc., Exscientia, Atomwise Inc., InveniAI LLC, Healx, Aitia, Cloud Pharmaceuticals Inc., Optibrium, Aiforia, BioSymetrics Inc., Collaborations Pharmaceuticals Inc., MAbSilico, Reverie Labs, Standigm Inc. , DeepMatter Group Limited, Variational AI Inc

North America was the largest region in the generative AI in drug discovery market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the generative artificial intelligence (AI) in drug discovery market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the generative artificial intelligence (AI) in drug discovery market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The generative AI in drug discovery market includes revenues earned by entities by providing services such as molecule generation, optimization, virtual screening, predictive modeling, de novo drug design, and consulting support. The market value includes the value of related goods sold by the service provider or included within the service offering. The generative AI in drug discovery market also includes sales of quantum computers, high-performance computing (HPC) clusters, tensor processing units, graphics processing units, and preclinical development tools. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Generative Artificial Intelligence (AI) In Drug Discovery Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on generative artificial intelligence (AI) in drug discovery market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for generative artificial intelligence (AI) in drug discovery ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The generative artificial intelligence (AI) in drug discovery market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of COVID-19 on supply chains and consumption patterns.

Scope

Table of Contents

1. Executive Summary

2. Generative Artificial Intelligence (AI) In Drug Discovery Market Characteristics

3. Generative Artificial Intelligence (AI) In Drug Discovery Market Trends And Strategies

4. Generative Artificial Intelligence (AI) In Drug Discovery Market - Macro Economic Scenario

5. Global Generative Artificial Intelligence (AI) In Drug Discovery Market Size and Growth

6. Generative Artificial Intelligence (AI) In Drug Discovery Market Segmentation

7. Generative Artificial Intelligence (AI) In Drug Discovery Market Regional And Country Analysis

8. Asia-Pacific Generative Artificial Intelligence (AI) In Drug Discovery Market

9. China Generative Artificial Intelligence (AI) In Drug Discovery Market

10. India Generative Artificial Intelligence (AI) In Drug Discovery Market

11. Japan Generative Artificial Intelligence (AI) In Drug Discovery Market

12. Australia Generative Artificial Intelligence (AI) In Drug Discovery Market

13. Indonesia Generative Artificial Intelligence (AI) In Drug Discovery Market

14. South Korea Generative Artificial Intelligence (AI) In Drug Discovery Market

15. Western Europe Generative Artificial Intelligence (AI) In Drug Discovery Market

16. UK Generative Artificial Intelligence (AI) In Drug Discovery Market

17. Germany Generative Artificial Intelligence (AI) In Drug Discovery Market

18. France Generative Artificial Intelligence (AI) In Drug Discovery Market

19. Italy Generative Artificial Intelligence (AI) In Drug Discovery Market

20. Spain Generative Artificial Intelligence (AI) In Drug Discovery Market

21. Eastern Europe Generative Artificial Intelligence (AI) In Drug Discovery Market

22. Russia Generative Artificial Intelligence (AI) In Drug Discovery Market

23. North America Generative Artificial Intelligence (AI) In Drug Discovery Market

24. USA Generative Artificial Intelligence (AI) In Drug Discovery Market

25. Canada Generative Artificial Intelligence (AI) In Drug Discovery Market

26. South America Generative Artificial Intelligence (AI) In Drug Discovery Market

27. Brazil Generative Artificial Intelligence (AI) In Drug Discovery Market

28. Middle East Generative Artificial Intelligence (AI) In Drug Discovery Market

29. Africa Generative Artificial Intelligence (AI) In Drug Discovery Market

30. Generative Artificial Intelligence (AI) In Drug Discovery Market Competitive Landscape And Company Profiles

31. Generative Artificial Intelligence (AI) In Drug Discovery Market Other Major And Innovative Companies

32. Global Generative Artificial Intelligence (AI) In Drug Discovery Market Competitive Benchmarking

33. Global Generative Artificial Intelligence (AI) In Drug Discovery Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Generative Artificial Intelligence (AI) In Drug Discovery Market

35. Generative Artificial Intelligence (AI) In Drug Discovery Market Future Outlook and Potential Analysis

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기